<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         dtd-version="1.1"
         xml:lang="en"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Slovenian Medical Journal</journal-title>
            <trans-title-group xml:lang="sl">
               <trans-title>Zdravniški vestnik</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2642</article-id>
         <article-id pub-id-type="publisher-id">2642</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Cardiovascular system</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="en">
               <subject>Cardiovascular system</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="en">Early giant cell arteritis: Identifying duration from symptoms to diagnosis, possible therapies and clinically-relevant cell dynamics</article-title>
            <alt-title alt-title-type="running-head" xml:lang="en">Early giant cell arteritis</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Burja</surname>
                  <given-names>Blaž</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Hočevar</surname>
                  <given-names>Alojzija</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Sodin Šemrl</surname>
                  <given-names>Snežna</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff2">2</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Lakota</surname>
                  <given-names>Katja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff2">2</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Rotar</surname>
                  <given-names>Žiga</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Ješe</surname>
                  <given-names>Rok</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Žigon</surname>
                  <given-names>Polona</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Čučnik</surname>
                  <given-names>Saša</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="aff" rid="aff3">3</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Nadkarni</surname>
                  <given-names>Suchita</given-names>
               </name>
               <xref ref-type="aff" rid="aff4">4</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Peretti</surname>
                  <given-names>Mauro</given-names>
               </name>
               <xref ref-type="aff" rid="aff4">4</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Praprotnik</surname>
                  <given-names>Sonja</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Tomšič</surname>
                  <given-names>Matija</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff id="aff1" xml:lang="en">
            <label>1</label>
            <institution>Department of Rheumatology, Division of Internal Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <aff id="aff2" xml:lang="en">
            <label>2</label>
            <institution>Faculty of Mathematics, Natural Science and Information Technologies, University of Primorska, Koper, Slovenia</institution>
         </aff>
         <aff id="aff3" xml:lang="en">
            <label>3</label>
            <institution>Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia</institution>
         </aff>
         <aff id="aff4" xml:lang="en">
            <label>4</label>
            <institution>William Harvey Research Institute, Queen Mary University of London, United Kingdom</institution>
         </aff>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Snežna Sodin Šemrl, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>8</month>
            <year>2018</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>8</month>
            <year>2018</year>
         </pub-date>
         <volume>87</volume>
         <issue>7–8</issue>
         <fpage>335</fpage>
         <lpage>48</lpage>
         <history>
            <date date-type="received">
               <day>13</day>
               <month>8</month>
               <year>2017</year>
            </date>
            <date date-type="accepted">
               <day>30</day>
               <month>11</month>
               <year>2017</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2018, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2018, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2018</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="en">
            <title>Abstract</title>
            <p>Giant cell arteritis (GCA) is the most prevalent primary systemic vasculitis in adults over 50 years of age in Europe. It affects large and medium sized arteries; the inflammatory process can ultimately lead to stenosis or occlusion of arterial lumen, resulting in severe clinical complications. In the last decade, imaging in diagnostics has importantly shortened the time to disease recognition (e.g. early GCA). Fast track clinics have led to a decrease in appearance of the most severe ischemic disease complications and lower costs of therapy. Despite fast access to appropriate therapy, the disease is chronic, and patients can experience relapses, which together with glucocorticoid therapy may lead to organ and tissue damage. Therefore, viable molecular and cellular target therapies are intensely explored. The major aims of our review were to: a) identify studies with indicated time from symptom development to diagnosis, b) explore promising molecular targets for GCA therapy, and c) identify clinically-relevant cellular phenotypes. The most promising molecular targets are IL-6, IL-12/IL-23, cytotoxic T–lymphocyte-associated protein-4, while therapies against TNF-α showed limited value and no clinical studies with secukimumab targeting IL-17 in GCA have been reported to date. Potential future therapeutic targets have been discussed, including targets in signaling pathways.</p>
         </abstract>
         <kwd-group xml:lang="en">
            <kwd>early giant cell arteritis</kwd>
            <kwd>biomarkers</kwd>
            <kwd>therapy targets</kwd>
            <kwd>cellular phenotypes</kwd>
            <kwd>T cells</kwd>
         </kwd-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Background">
         <label>1</label>
         <title>Background</title>
         <p>The article presents a systematic review of giant cell arteritis (GCA): its clinical course and the importance of early diagnosis and treatment for the prevention of complications such as blindness and stroke.</p>
      </sec>
      <sec id="s2" sec-type="Introduction">
         <label>2</label>
         <title>Introduction</title>
         <p>Giant cell arteritis (GCA) is the most prevalent systemic vasculitis of the adult population (persons over 50 years of age) in the western world (<xref ref-type="bibr" rid="b1">1</xref>). It is an inflammatory autoimmune disease with predominant involvement of large and medium sized arteries. It typically affects branches of the external carotid artery, as indicated also by its old name: temporal arteritis (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b3">3</xref>). This term was abandoned as a synonym for GCA already in 1994 at the Chapel Hill Consensus Conference (CHCC), because the disease may affect also other arteries, mainly the aorta and large branches of the aortic arch (e.g. subclavian arteries, axillary arteries, initial segment of brachial arteries). This is recognized in the updated definition adopted at the CHCC in 2012 (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b5">5</xref>). The estimated prevalence of GCA in persons over 50 years of age is 1:750, while its incidence increases about 25-fold between the age groups 50–59 years and over 80 (<xref ref-type="bibr" rid="b6">6</xref>). The estimated annual incidence of GCA in Slovenia is 9.7 (95 % CI 8.1–15.5)/10<sup>5</sup> in persons over 50 years of age (<xref ref-type="bibr" rid="b7">7</xref>).</p>
         <p>Gender are race are risk factors for GCA; between 65 % and 75 % of patients are women (<xref ref-type="bibr" rid="b8">8</xref>). The incidence is highest in the Caucasian population of northern Europe (about 20/10<sup>5</sup> persons over 50) and decreases towards the south. Because of the late onset, environmental factors and life style (smoking, slender build) are believed to affect the susceptibility for the disease (<xref ref-type="bibr" rid="b8">8</xref>).</p>
         <sec id="s2.1" sec-type="Clinical picture">
            <label>2.1</label>
            <title>Clinical picture</title>
            <p>The clinical picture of GCA includes a wide range of symptoms and signs, which are partly general, caused by systemic inflammation, and partly specific, directly related to ischaemia due to reduced patency of arteries (<xref ref-type="bibr" rid="b3">3</xref>). The most common specific symptom is newly developed headache. Other frequent complaints are claudication pain while chewing, scalp tenderness, and pain when combing hair. The temporal artery may be swollen and tender to pressure. Occlusion of arteries nourishing the eye may lead to visual symptoms, most often manifested as double vision, blurred vision, or sudden transient (amaurosis fugax) or permanent loss of vision. Permanent visual loss is often preceded by other transient symptoms, and such warning signals warrant our full attention. Timely treatment can prevent permanent blindness. Untreated patients with unilateral loss of vision have a 50 % risk of losing sight in the other eye within a few days (<xref ref-type="bibr" rid="b9">9</xref>). A large meta-analysis has identified jaw claudication and double vision as the best predictors of GCA (<xref ref-type="bibr" rid="b10">10</xref>). Because of the high risk of permanent blindness (14–20 % of patients) (<xref ref-type="bibr" rid="b11">11</xref>-<xref ref-type="bibr" rid="b13">13</xref>) and stroke (2–4 % of patients) (<xref ref-type="bibr" rid="b14">14</xref>), GCA is classified as a rheumatological emergency.</p>
            <p>Involvement of large arteries, present in 30–83 % of patients, is most often manifested by limb claudication and asymmetrical or absent limb pulses (<xref ref-type="bibr" rid="b15">15</xref>). Involvement of the aorta, established in 10–18 % of cases, may lead to the development of an aneurysm and aortic dissection (<xref ref-type="bibr" rid="b15">15</xref>). Another characteristic of the disease is systemic inflammation with elevated inflammatory parameters, which may dominate the clinical picture with general symptoms, such as fever, weight loss, anorexia, fatigue and myalgia.</p>
            <p>Rheumatic polymyalgia (PMR) is closely related to GCA; it occurs in 40–50 % of GCA patients (<xref ref-type="bibr" rid="b16">16</xref>,<xref ref-type="bibr" rid="b17">17</xref>), while GCA is diagnosed in 15 % of patients with PMR (<xref ref-type="bibr" rid="b18">18</xref>). Some authors describe the two conditions as different manifestations of the same illness.</p>
         </sec>
         <sec id="s2.2" sec-type="Diagnosis">
            <label>2.2</label>
            <title>Diagnosis</title>
            <p>Age over 50 years is one of the five classification criteria for GCA published by the American College of Rheumatology (ACR). The others are newly developed headache, clinically abnormal temporal artery, elevated erythrocyte sedimentation rate (ESR ≥ 50 mm/h), and abnormal temporal artery biopsy (<xref ref-type="bibr" rid="b19">19</xref>). For vasculitis to be classified as GCA, at least three of the five criteria must be met, which gives a sensitivity of 93 % and a specificity of 91 %. It must be pointed out that these are classification criteria rather than diagnostic ones. Thus, they do not allow early recognition of the disease. We use them as an aid in diagnostic evaluation, but the diagnosis is clinical (<xref ref-type="bibr" rid="b20">20</xref>).</p>
            <p>Until recently, temporal artery biopsy was the only “gold standard” for confirming the diagnosis of GCA. Today we know, however, that histopathological findings in the vessel wall are not easy to interpret, that the vascular inflammation is segmental (the inflamed segment may be missed on biopsy), and temporal artery biopsy is negative in more than half of cases of extracranial involvement. Thus, temporal artery biopsy is currently losing its importance as the main and only confirmation method for GCA (<xref ref-type="bibr" rid="b8">8</xref>). At present, the diagnosis is based on imaging studies, such as arterial ultrasound (US), computed tomography and/or magnetic resonance (CT/MR) angiography, and positron emission tomography (PET/CT). Besides establishing the diagnosis, these examinations allow us to localize the disease and, at least partly, monitor its course. With the first three investigations, we are able to estimate structural changes (vessel wall thickening, stenosis/occlusion, thrombosis etc.), while PET permits early assessment of functional/inflammatory activity of the disease in the vessel wall - possibly even before the occurrence of structural changes. US has priority over other imaging techniques because it is non-invasive, widely accessible, inexpensive, and does not expose the patient to ionizing radiation. It is suitable for evaluation of all large arteries except the thoracic aorta. Two characteristic US findings in GCA are the halo sign and the compression sign (swelling of inflamed vessel wall does not disappear on application of pressure). The first multicentre study on the usefulness of ultrasonography in the diagnosis of GCA (TABUL) has confirmed the important role of US in early recognition of the disease. It showed that US examination of the temporal artery has higher sensitivity and similar specificity compared to biopsy (<xref ref-type="bibr" rid="b21">21</xref>,<xref ref-type="bibr" rid="b22">22</xref>). US follow-up is important in predicting treatment outcome (<xref ref-type="bibr" rid="b23">23</xref>). Besides US examination, PET/CT is an important diagnostic method in suspected involvement of extracranial large arteries, often manifested by fever of unclear origin or unexplained inflammatory syndrome. PET imaging allows us to localize the disease, but its role in predicting treatment outcome is still unclear (<xref ref-type="bibr" rid="b23">23</xref>).</p>
         </sec>
         <sec id="s2.3" sec-type="Treatment">
            <label>2.3</label>
            <title>Treatment</title>
            <p>Glucocorticoid (GC) therapy effectively controls systemic infection and in most cases prevents the development of acute complications, e.g. permanent loss of vision. Nevertheless, about 50 % of patients experience relapses during tapering of the GC dose (<xref ref-type="bibr" rid="b24">24</xref>). New drugs capable of maintaining disease remission are intensely explored (<xref ref-type="bibr" rid="b25">25</xref>). Recommendations of the European League against Rheumatism (EULAR) from 2008 for GCA management include the use of immunosuppressive agents to reduce the side effects of glucocorticoids and maintain better disease control (<xref ref-type="bibr" rid="b26">26</xref>). Methotrexate (MTX), formerly reported to have low efficacy, is now often used in relapses, since recent studies have documented considerable reductions in relapse rates when MTX is given early as an adjunct to GC (<xref ref-type="bibr" rid="b27">27</xref>-<xref ref-type="bibr" rid="b30">30</xref>). Some authors also use leflunomide as a corticosteroid-sparing agent in GCA (<xref ref-type="bibr" rid="b31">31</xref>). Recently, the U.S. Food and Drug Administration (FDA) has approved the use of tocilizumab, a monoclonal interleukin (IL) 6 receptor antibody, as the first biological drug for targeted treatment of GCA (<xref ref-type="bibr" rid="b32">32</xref>,<xref ref-type="bibr" rid="b33">33</xref>); trials with ustekinumab, an IL-12/23 inhibitor, are also underway (<xref ref-type="bibr" rid="b34">34</xref>,<xref ref-type="bibr" rid="b35">35</xref>).</p>
         </sec>
      </sec>
      <sec id="s3" sec-type="Early GCA">
         <label>3</label>
         <title>Early GCA</title>
         <p>Early diagnosis and treatment of GCA have a key influence on disease outcome (<xref ref-type="bibr" rid="b36">36</xref>). We gathered data from studies with indicated time from onset of symptoms to diagnosis (<xref ref-type="bibr" rid="b24">24</xref>,<xref ref-type="bibr" rid="b37">37</xref>-<xref ref-type="bibr" rid="b47">47</xref>). The selected studies were performed after the year 2010 and included at least 20 patients (Table 1). In most of these studies, time to diagnosis was longer than one month. The shortest times to diagnosis were reported in 2016 by Carbonella A et al. (<xref ref-type="bibr" rid="b37">37</xref>) (average 3 ± 1.9 weeks) and by Hočevar A et al. (<xref ref-type="bibr" rid="b24">24</xref>) (median value 30 days, interquartile range 12–71). Early diagnosis is important because early initiation of treatment increases the likelihood of preventing serious complications. Waiting times for a rheumatology consultation vary from country to country. In some countries, patients receive glucocorticoids from their primary care physicians before referral to a rheumatologist, whereas in some other countries, fast-track specialized outpatient clinics for GCA permit rapid diagnostic assessment.</p>
         <p>Analysis of ocular complications reveals a somewhat different picture. Singh et al. (2015) found no differences in time from onset of symptoms to diagnosis between patients with visual complications or without them (median 26 and 24 days, respectively) (<xref ref-type="bibr" rid="b48">48</xref>). In a 25-year longitudinal study conducted in Spain, time to diagnosis was 10.3 (± 11) weeks, and the results showed that a decrease in the frequency of visual complications could not be attributed to a shorter time to diagnosis (<xref ref-type="bibr" rid="b49">49</xref>). Recent studies, however, suggest the opposite. One of them, performed by Hočevar et al., found unilateral blindness in 5.9 % (4/68) of GCA patients. The number of cases of permanent visual loss has decreased over the past few years, mainly as a consequence of increased physician awareness of GCA (<xref ref-type="bibr" rid="b50">50</xref>). Early recognition of the disease and prompt initiation of glucocorticoid therapy are the key to reducing serious complications.</p>
      </sec>
      <sec id="s4" sec-type="Molecular targets in GCA therapy">
         <label>4</label>
         <title>Molecular targets in GCA therapy</title>
         <p>GCA is currently treated with high initial doses of glucocorticoids, which are very effective. The GC dose is then gradually reduced. The entire treatment usually lasts 2 years. Because of the side effects of prolonged GC therapy and frequent relapses upon dose reduction, new treatment options are intensely explored. Potential therapeutic targets are both cytokine and non-cytokine molecules.</p>
         <sec id="s4.1" sec-type="Therapies targeting cytokine molecules">
            <label>4.1</label>
            <title>Therapies targeting cytokine molecules</title>
            <p>Interleukin (IL)-6. Serum levels of IL-6, the main trigger for the synthesis of C-reactive protein (CRP) and serum amyloid A (SAA), are significantly elevated in untreated patients with GCA; the levels transiently decrease after treatment, and are often higher in patients with chronic disease compared to healthy subjects (<xref ref-type="bibr" rid="b8">8</xref>). Significantly higher IL-6 levels in GCA patients compared to healthy blood donors were demonstrated by several methods in a number of studies (<xref ref-type="bibr" rid="b51">51</xref>-<xref ref-type="bibr" rid="b59">59</xref>). Similarly, expression levels of IL-6 messenger ribonucleic acid (mRNK) in temporal artery biopsies from GCA patients were significantly higher compared to controls (<xref ref-type="bibr" rid="b52">52</xref>,<xref ref-type="bibr" rid="b60">60</xref>,<xref ref-type="bibr" rid="b61">61</xref>).</p>
            <table-wrap position="anchor" id="table1">
               <label>Table 1:</label>
               <caption>
                  <p> Studies with indicated time from onset of symptoms to diagnosis of GCA.</p>
               </caption>
               <table>
                  <colgroup>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th>Source</th>
                        <th>Title</th>
                        <th>
                           <p>No. of GCA</p>
                           <p>patients</p>
                        </th>
                        <th>Time from onset of symptoms to diagnosis</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>Carbonella A. et al., J Am Geriatr Soc. 2016 (<xref ref-type="bibr" rid="b37">37</xref>)</td>
                        <td>Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of GCA: Comparison with Corticosteroids Alone</td>
                        <td align="right">47</td>
                        <td align="right">3.0 ± 1.9 weeks</td>
                     </tr>
                     <tr>
                        <td>
                           <p>Hocevar A.</p>
                           <p>et al., Medicine<italic> </italic>(Baltimore), 2016 (<xref ref-type="bibr" rid="b24">24</xref>)</p>
                        </td>
                        <td>Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study</td>
                        <td align="right">68</td>
                        <td align="right">30 (14-71) days</td>
                     </tr>
                     <tr>
                        <td>
                           <p>Seelinger B</p>
                           <p>et al., Rheumatology, 2015 (<xref ref-type="bibr" rid="b38">38</xref>)</p>
                        </td>
                        <td>Predictors of Delay in Diagnosis of Giant Cell Arteritis and Antineutrophil Cytoplasm Antibody Associated Vasculitides: Analysis of Data from the Diagnostic &amp; Classification Criteria in Vasculitis Study</td>
                        <td align="right">230</td>
                        <td align="right">31 (13-85) days</td>
                     </tr>
                     <tr>
                        <td>Ezeonyeji A.N. et al., Clin Rheumatology, 2011 (<xref ref-type="bibr" rid="b39">39</xref>)</td>
                        <td>Delays in recognition and management of GCA: results from a retrospective audit</td>
                        <td align="right">65</td>
                        <td align="right">35 (2-140) days</td>
                     </tr>
                     <tr>
                        <td>Chandran A.K. et al., Scand J Rheumatol, 2015 (<xref ref-type="bibr" rid="b40">40</xref>)</td>
                        <td>The Incidence of GCA in Olmsted County Minnesota, Over a Sixty Year Period 1950–2009</td>
                        <td align="right">74</td>
                        <td align="right">1.6 ± 2.6 months</td>
                     </tr>
                     <tr>
                        <td>Baldini M. et al., Arthritis &amp; Rheumatism, 2012 (<xref ref-type="bibr" rid="b41">41</xref>)</td>
                        <td>Selective Up-Regulation of the Soluble Pattern-Recognition Receptor Pentraxin 3 and of VEGF in GCA</td>
                        <td align="right">30</td>
                        <td>
                           <p>1.90 ± 0.35</p>
                           <p>(0.12–8) months</p>
                        </td>
                     </tr>
                     <tr>
                        <td>Ciccia F. et al., Ann Rheum Dis, 2016 (<xref ref-type="bibr" rid="b42">42</xref>)</td>
                        <td>Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in GCA</td>
                        <td align="right">50</td>
                        <td align="right">2 ± 11 months</td>
                     </tr>
                     <tr>
                        <td>
                           <p>Labarca C.</p>
                           <p>et al., Rheumatology (Oxford), 2016 (<xref ref-type="bibr" rid="b43">43</xref>)</p>
                        </td>
                        <td>Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study</td>
                        <td align="right">286</td>
                        <td align="right">2.1 (0.9–4.4) months</td>
                     </tr>
                     <tr>
                        <td>Muller G. et al., Geriatr Gerontol Int, 2015 (<xref ref-type="bibr" rid="b44">44</xref>)</td>
                        <td>GCA (Horton’s disease) in very elderly patients aged 80 years and older: A study of 25 cases</td>
                        <td align="right">25</td>
                        <td align="right">2.2 months</td>
                     </tr>
                     <tr>
                        <td>
                           <p>Muratore F.</p>
                           <p>et al., Rheumatology (Oxford), 2015 (<xref ref-type="bibr" rid="b45">45</xref>)</p>
                        </td>
                        <td>Large-vessel GCA: a cohort study</td>
                        <td align="right">120 LV-GCA</td>
                        <td align="right">3.5 (2–7.2) months</td>
                     </tr>
                     <tr>
                        <td>Alba M.A. et al., J Clin Rheumatol. 2012 (<xref ref-type="bibr" rid="b46">46</xref>)</td>
                        <td>GCA in Mexican patients</td>
                        <td align="right">22</td>
                        <td align="right">67 ± 83.6 days</td>
                     </tr>
                     <tr>
                        <td>Alba M.A. et al., Medicine (Baltimore). 2014 (<xref ref-type="bibr" rid="b47">47</xref>)</td>
                        <td>Relapses in Patients with GCA: Prevalence, characteristics and associated clinical findings in a longitudinally followed cohort of 106 patients</td>
                        <td align="right">106</td>
                        <td align="right">16 ± 21 tednov</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <p>Legend: BAFF: B-cell activating factor; CXCL13: chemokine (C-X-C motif) ligand 13; NA: not available; HBD: apparently healthy blood donors; GCA: giant cell arteritis; LT-β: Limfotoksin-beta; LV-GCA: large-vessel GCA; PMR: polymyalgia rheumatica. The data were taken from sources »ad verbum«.</p>
               </table-wrap-foot>
            </table-wrap>
            <p>Dasgupta B and Panayi GS (<xref ref-type="bibr" rid="b62">62</xref>) reported that IL-6 activity was elevated in all patients with untreated GCA. Six years ago, anti–IL-6 receptor therapy was proposed for the treatment of GCA (<xref ref-type="bibr" rid="b63">63</xref>), following the publication of several cases of rapidly induced remission by IL-6 blockade (<xref ref-type="bibr" rid="b64">64</xref>). In 2013, Unizony SH et al. (<xref ref-type="bibr" rid="b25">25</xref>) published a justification, design and protocol for a large clinical trial of tocilizumab (anti-IL-6R) with 250 included patients. The authors proposed the hypothesis that disruption of the IL-6 signalling pathway could have a favourable effect on GCA outcome. Preliminary results on the use of anti-IL-6 are encouraging (<xref ref-type="bibr" rid="b65">65</xref>). A recent phase 2 randomized double-blind placebo-controlled trial was the first to demonstrate the efficacy of tocilizumab in inducing and maintaining remission (<xref ref-type="bibr" rid="b66">66</xref>). The same group of researchers also found a 55 % relapse rate in patients after termination of tocilizumab treatment, the median time to relapse being 5 months. Their results showed that long-term administration of tocilizumab is necessary for the maintenance of remission. In a recent report, Stone et al. evaluated the efficacy and safety of tocilizumab in patients receiving the drug for up to 52 weeks as part of the GiACTA randomized double-blind placebo-controlled trial, and concluded that tocilizumab in combination with 26-week GC treatment was more effective than GC monotherapy (<xref ref-type="bibr" rid="b68">68</xref>). On the other hand, a multicentre retrospective study of tocilizumab in 34 patients with GCA called attention to serious side effects of the drug that occurred in 17 % of the patients: neutropenia (3 patients), infection (1 patient developed tuberculous pericarditis and 1 died of septic shock), and liver cirrhosis (in a patient with concurrent MTX therapy) (<xref ref-type="bibr" rid="b69">69</xref>).</p>
            <p>IL-1 receptor antagonist. In a study including 3 patients with GCA, treatment with an IL-1 receptor antagonist (anakinra) led to improvement in symptoms and inflammatory markers (<xref ref-type="bibr" rid="b70">70</xref>,<xref ref-type="bibr" rid="b71">71</xref>). Also relevant is the finding that IL-1Ra knockout mice developed large-vessel vasculitis (<xref ref-type="bibr" rid="b72">72</xref>). Additional studies are necessary for further evaluation of the drug, since IL-1 receptor antagonist has less favourable pharmacokinetic properties, and an excess over endogenous IL-1 is required for its efficacy (<xref ref-type="bibr" rid="b70">70</xref>,<xref ref-type="bibr" rid="b71">71</xref>). Preparations are underway for a phase 3 GiAnT trial of anakinra (US Clin trial.gov identifier NCT02902731) with the main aim to determine whether the addition of anakinra to GC therapy can prevent GCA relapses.</p>
            <p>IL-1β. A clinical trial of gevokizumab (an anti-IL-1β monoclonal antibody) in patients with relapsing GCA (European Clinical Trials Database identifier 2013–002778–38) is in progress. Dasgupta B, reporting on the use of anti-I-1β, stated that IL-1 is produced by the majority of activated circulatory monocytes (<xref ref-type="bibr" rid="b72">72</xref>). IL-1 originating from the vessel wall correlates with the systemic inflammatory response in patients with GCA.</p>
            <p>IL-12/IL-23. Ustekinumab, a monoclonal antibody against IL-12/23p40, is effective in the treatment of Crohn’s disease and psoriasis. Since it inhibits Th1 (IL-12, IFN-γ) and Th17 (IL-23, IL-1) cell responses, it could be effective also in the treatment of large-vessel vasculitides, such as GCA. Conway R et al. reported on a study of 14 patients with refractory GCA (<xref ref-type="bibr" rid="b34">34</xref>), defined as failure to taper GC (prednisolone) below 10 mg/day or symptoms of active disease with at least two relapses (<xref ref-type="bibr" rid="b19">19</xref>). Ustekinumab allowed a significant reduction of the GC dose and discontinuation of other immunosuppressive drugs. In 2016, Conway R et al. published data on long-term efficacy of ustekinumab, which led to significant reductions in doses of glucocorticoids and acute-phase proteins in patients with refractory GCA (<xref ref-type="bibr" rid="b35">35</xref>).</p>
            <p>IL-17. This cytokine is thought to play an important role in the development of vascular wall inflammation in GCA. Significantly increased expression of IL-17 has been measured in temporal artery biopsies from patients with GCA by the method of quantitative polymerase chain reaction (QPCR) (<xref ref-type="bibr" rid="b42">42</xref>,<xref ref-type="bibr" rid="b52">52</xref>,<xref ref-type="bibr" rid="b73">73</xref>,<xref ref-type="bibr" rid="b74">74</xref>). Moreover, mice deficient in interferon regulatory factor 4 binding protein, which inhibits IL-17A, have been shown to develop large vessel vasculitis (<xref ref-type="bibr" rid="b75">75</xref>). Marquez et al. (2014) published a large meta-analysis, which included 1,266 biopsy-proven GCA patients and 3,779 healthy blood donors from four European countries (Spain, Italy, Germany and Norway). The authors reported a novel association between polymorphisms within the IL-17A locus and GCA (<xref ref-type="bibr" rid="b76">76</xref>). From peripheral white blood cells, they extracted genomic deoxyribonucleic acid (DNA) and analysed it for five single nucleotide polymorphisms (SNPs) located at the IL-17A locus. They identified three polymorphisms that represent a risk for the development of GCA. Surprisingly, they found the strongest association with rs2275913, located within a binding motif for the transcription nuclear factor of activated T cells (NFAT), a central regulator of the IL-17A promoter (<xref ref-type="bibr" rid="b76">76</xref>).</p>
            <p>IL-17 inhibition has been tested in several clinical studies of different autoimmune diseases, using different biological drugs (sekukinumab, ixekizumab, and brodalumab) and agents (ABT-122, RG4934, RG7624, SHC-900117, and SHC-900222, also called MK-3222). Positive and negative results were obtained, and the complexity in predicting the patient’s response to treatment directed against IL-17 was described. Despite conflicting results, it is clear that the circulating values of IL-17A in healthy blood donors and GCA patients are very low (<xref ref-type="bibr" rid="b77">77</xref>). The role of IL-17A as a target molecule in the treatment of patients with GCA is currently unclear. There have been no studies with IL-17 inhibitors published to date.</p>
            <p>TNF-α. TNF-α is significantly increased in blood serum and temporal artery biopsies from patients with GCA, both at the protein level (<xref ref-type="bibr" rid="b53">53</xref>,<xref ref-type="bibr" rid="b59">59</xref>,<xref ref-type="bibr" rid="b78">78</xref>) and the mRNA level (<xref ref-type="bibr" rid="b60">60</xref>,<xref ref-type="bibr" rid="b79">79</xref>). However, it has not proved to be a good candidate for therapy. Clinical trials of TNF-α inhibitors (infliximab, etanercept and adalimumab) in patients with GCA failed to achieve good treatment outcomes (<xref ref-type="bibr" rid="b80">80</xref>-<xref ref-type="bibr" rid="b82">82</xref>). EULAR guidelines from the year 2009 do not recommend using TNF-α inhibitors in the treatment of GCA.</p>
         </sec>
         <sec id="s4.2" sec-type="Other non-cytokine molecules">
            <label>4.2</label>
            <title>Other non-cytokine molecules</title>
            <p>Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) – abatacept. Abatacept is a fusion protein composed of an IgG1 fragment fused to the extracellular domain of CTLA-4. It binds to CD80/86 on antigen presenting cells and prevents their binding to CD28 on the T cell and their activation. Langford et al. (<xref ref-type="bibr" rid="b83">83</xref>) recently completed a multicentre clinical trial (Clinicaltrials.gov identifier: NCT00556439) in which patients with GCA and Takayasu arteritis received induction treatment with abatacept 10 mg/kg intravenously on days 1, 15, 29 and week 8, together with oral prednisolone. From the preliminary data for GCA published in abstract form (<xref ref-type="bibr" rid="b83">83</xref>), it appears that 41 patients with GCA underwent randomization at week 12; 20 patients continued to receive abatacept and 21 were switched to placebo. The patients treated with abatacept had a significantly higher relapse-free survival rate at 12 months (48 % vs. 31 %) and a significantly longer duration of remission (9.9 vs. 3.9 months) than the patients who received placebo. Although the results are promising, they will require further confirmation in a larger series. A critical review of abatacept and other latest advances in the management of GCA was recently published by Koster MJ et al. (<xref ref-type="bibr" rid="b84">84</xref>).</p>
            <p>CD20. GCA is considered primarily a T-cell disease, but B-cell dysregulation is present as well (<xref ref-type="bibr" rid="b84">84</xref>). The potential use of rituksimab in GCA was proposed in 2 case reports in 2005 (<xref ref-type="bibr" rid="b85">85</xref>) and 2007 (<xref ref-type="bibr" rid="b86">86</xref>).</p>
            <p>Rho kinase (ROCK). Expression of ROCK mRNA is elevated in temporal artery biopsies from patients with GCA (<xref ref-type="bibr" rid="b87">87</xref>). Altered ROCK activity could play a role in vascular inflammation. Future studies should address the questions: how to inhibit ROCK activity, and how this would affect the physiological characteristics of immune cells, such as signalling and phagocytosis.</p>
            <p>Neurogenic locus notch homologue protein (NOTCH). In humanized mouse models, NOTHC inhibition was effective in downregulating the Th17 response and suppressing the Th1 response while depleting T-cell infiltrates from the vascular lesion (<xref ref-type="bibr" rid="b88">88</xref>). Disruption of the NOTCH signalling pathway strongly inhibits T-cell activation in the early and established phases of vascular inflammation. Modulation of the NOTCH response has been proposed as a new strategy for immunosuppressive treatment of large vessel vasculitides. Since studies of both the ROCK and the NOTCH pathways are still at a pre-clinical stage, the two pathways are for the time being only potential therapeutic targets in GCA.</p>
            <p>Janus kinase inhibitor (JAK). A clinical study evaluating the safety and efficacy of baricitinib (a JAK1 and JAK2 inhibitor) in patients with GCA is in progress (Clinical trial identifier NCT03026504).</p>
         </sec>
      </sec>
      <sec id="s5"
           sec-type="Clinically significant cell dynamics involved in the development of GCA – selected studies">
         <label>5</label>
         <title>Clinically significant cell dynamics involved in the development of GCA – selected studies</title>
         <p>Of primary importance for GCA immunopathology at the cell level are the Th1 (in the chronic phase of the disease) and Th17 (in the early phase) cell responses (<xref ref-type="bibr" rid="b89">89</xref>). Fernandez-Fernandez FJ (<xref ref-type="bibr" rid="b90">90</xref>) recently proposed using alfacalcidol, a hormone preparation of vitamin D, which unlike vitamin D2 or D3, has <italic>in vivo</italic>
            <italic> </italic>and<italic> </italic>
            <italic>in vitro</italic> immunomodulatory effects, as adjuvant treatment in GCA. Alfacalcidol could affect the Treg/Th17 cell ratio. This was confirmed by Zold et al. (<xref ref-type="bibr" rid="b91">91</xref>), who showed that 1 µg of alfacalcidol daily reduced the levels of IL-6. IL-17, IL-12 and IFN-γ, as well as the proportion of circulating Th1 and Th17 cells, while increasing the number of circulating Treg cells and restoring their inhibitory function. The role of alfacalcidol in the treatment of GCA warrants further study. The active form of vitamin D (1,25 dihydroxycholecalciferol), in combination with IL-2, has also been shown to suppress the Th1 and Th17 cell responses and stimulate Treg cells (<xref ref-type="bibr" rid="b92">92</xref>).</p>
         <p>Samson M et al. (<xref ref-type="bibr" rid="b93">93</xref>) were the first to show that the number of Treg cells is decreased in patients with GCA, and that CD161+CD4+ T lymphocytes, differentiated into Th1 and Th17 cells, are involved in the pathogenesis of GCA. Fundamental differences were found between Th1 cells and Th17 cells regarding their dependency on acetyl-coA carboxylase 1-mediated <italic>de novo</italic> fatty acid synthesis, which might be exploited as a new strategy for metabolic immune modulation of Th17 cell-mediated inflammatory diseases (<xref ref-type="bibr" rid="b94">94</xref>). Circulating T cell (CD8+) values are decreased in GCA, and the decrease correlates with the degree of carotid artery stenosis (<xref ref-type="bibr" rid="b95">95</xref>,<xref ref-type="bibr" rid="b96">96</xref>). Samson M et al. (<xref ref-type="bibr" rid="b97">97</xref>) also reported on the predictive role of CD8+ T cells. Interestingly, neutrophils are also thought to have a potential role in the development of GCA, as reported in 2014 by Nadkarni S et al. (<xref ref-type="bibr" rid="b98">98</xref>), who described the existence of an increased inflammatory phenotype during tapering of the GC dose. The authors described a specific neutrophil phenotype (high expression of CD62L and Annexin A1 (AnxA1) and low CD11b) appearing early in the course of the disease during treatment with high GC doses. Upon tapering of GC doses, they observed an inflammatory phenotype (low CD62L, high CD11b, high AnxA1) appearing in a certain group of patients, which could predict undesired complications and relapses. It must be pointed out that the study included a small number of patients. Thus, a greater number of patients will be necessary to assess the potential predictive role of this neutrophil phenotype. The study also highlighted an interesting association between certain previously mentioned cytokines, as it analysed the values of IL-6 and IL-17 during tapering of GC doses. Incubation of healthy neutrophil granulocytes with pathological concentrations of the two cytokines (such as are present in GCA) promotes the inflammatory neutrophil phenotype, which represents a possible causative relationship between circulatory and cellular mechanisms involved in the development of relapsing disease and adverse cardiovascular events.</p>
      </sec>
      <sec id="s6" sec-type="Conclusion">
         <label>6</label>
         <title>Conclusion</title>
         <p>Shortening the time interval from symptom onset to diagnosis and introducing new treatment options could improve the prevention of serious complications in patients with GCA. Fast-track specialized diagnostic outpatient clinics for GCA are currently the most effective approach to the prevention of complications and better control of the disease. Clinical trials of new therapeutic options are underway, the most promising currently being tocilizumab. Although newer approaches to treatment are mainly directed against single target molecules, GCA calls for a broad view, the disease being complex and of multifactorial aetiology, with the defect at several levels of cellular and humoral immunity. Therefore, we believe that knowledge of the cell dynamics and determination of neutrophil granulocytes and the T cell and B cell populations could contribute to predicting the disease process, relapses, and the patient’s response to therapy.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Levin</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ward</surname>
                     <given-names>TN</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Horton’s disease: past and present</article-title>. 
                    <source>Curr Pain Headache Rep</source>. 
                    <year>2005</year>
                    <month>Aug</month>;
                    <volume>9</volume>(
                    <issue>4</issue>):
                    <fpage>259</fpage>–
                    <lpage>63</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s11916-005-0033-4</pub-id>
                    <pub-id pub-id-type="pmid">16004841</pub-id>
                    <issn>1531-3433</issn>                    
                </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Watts</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Suppiah</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Merkel</surname>
                     <given-names>PA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Luqmani</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Systemic vasculitis—is it time to reclassify?</article-title>
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2011</year>
                    <month>Apr</month>;
                    <volume>50</volume>(
                    <issue>4</issue>):
                    <fpage>643</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/keq229</pub-id>
                    <pub-id pub-id-type="pmid">20647295</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b3">
            <label>3. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Borchers</surname>
                     <given-names>AT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gershwin</surname>
                     <given-names>ME</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment</article-title>. 
                    <source>Autoimmun Rev</source>. 
                    <year>2012</year>
                    <month>May</month>;
                    <volume>11</volume>(
                    <issue>6-7</issue>):
                    <fpage>A544</fpage>–
                    <lpage>54</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.autrev.2012.01.003</pub-id>
                    <pub-id pub-id-type="pmid">22285588</pub-id>
                    <issn>1568-9972</issn>
                </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jennette</surname>
                     <given-names>JC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Falk</surname>
                     <given-names>RJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bacon</surname>
                     <given-names>PA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Basu</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cid</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ferrario</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>65</volume>(
                    <issue>1</issue>):
                    <fpage>1</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.37715</pub-id>
                    <pub-id pub-id-type="pmid">23045170</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ness</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bley</surname>
                     <given-names>TA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schmidt</surname>
                     <given-names>WA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lamprecht</surname>
                     <given-names>P</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The diagnosis and treatment of giant cell arteritis</article-title>. 
                    <source>Dtsch Arztebl Int</source>. 
                    <year>2013</year>
                    <month>May</month>;
                    <volume>110</volume>(
                    <issue>21</issue>):
                    <fpage>376</fpage>–
                    <lpage>85</lpage>.
                    <pub-id pub-id-type="pmid">23795218</pub-id>
                    <issn>1866-0452</issn>
                </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6. </label>
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nesher</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Giant cell arteritis</chapter-title>. In: 
                    <person-group person-group-type="author">
                    <name name-style="western">
                     <surname> Shoenfeld</surname>
                     <given-names>Y</given-names>
                  </name>,
                    <name name-style="western">
                     <surname>Cervera</surname>
                     <given-names>R</given-names>
                  </name>,  
                    <name name-style="western">
                     <surname>Gershwin</surname>
                     <given-names>ME</given-names>
                  </name>,
                    <role>eds</role>   
                    </person-group>.
                    <source>Diagnostic Criteria in Autoimmune Diseases</source>. 
                    <publisher-loc>Totowa NJ</publisher-loc>:
                    <publisher-name>Humana Press</publisher-name>;
                    <year>2008</year>. pp. 
                    <fpage>73</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/978-1-60327-285-8_13</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7. </label>
            <mixed-citation publication-type="webpage">
                    <person-group>
                  <name name-style="western">
                     <surname/>
                  </name>
               </person-group>.
                    <source>The Incidence Rate of Giant Cell Arteritis in Slovenia</source>. 
                    <year>2015</year>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2016-08-11">cited 2016 Aug 11</date-in-citation>].
                    <comment>Available from:<uri>http://acrabstracts.org/abstract/the-incidence-rate-of-giant-cell-arteritis-in-slovenia/</uri>
               </comment>. 
                </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goronzy</surname>
                     <given-names>JJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant-cell arteritis and polymyalgia rheumatica</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>371</volume>(
                    <issue>17</issue>):
                    <fpage>1653</fpage>.
                    <pub-id pub-id-type="pmid">25337759</pub-id>
                    <issn>1533-4406</issn>
                </mixed-citation>
         </ref>
         <ref id="b9">
            <label>9. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dejaco</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Duftner</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Buttgereit</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matteson</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.</article-title> Rheumatology (Oxford). 
                    <year>2016</year>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/kew273</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bienvenu</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ly</surname>
                     <given-names>KH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lambert</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Agard</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>André</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Benhamou</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Groupe d’Étude Français des Artérites des gros Vaisseaux, under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares</collab>
                    </person-group>. 
                    <article-title>Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)</article-title>. 
                    <source>Rev Med Interne</source>. 
                    <year>2016</year>
                    <month>Mar</month>;
                    <volume>37</volume>(
                    <issue>3</issue>):
                    <fpage>154</fpage>–
                    <lpage>65</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.revmed.2015.12.015</pub-id>
                    <pub-id pub-id-type="pmid">26833145</pub-id>
                    <issn>0248-8663</issn>
                </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Liozon</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ly</surname>
                     <given-names>KH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Robert</surname>
                     <given-names>PY</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Ocular complications of giant cell arteritis</article-title>. 
                    <source>Rev Med Interne</source>. 
                    <year>2013</year>
                    <month>Jul</month>;
                    <volume>34</volume>(
                    <issue>7</issue>):
                    <fpage>421</fpage>–
                    <lpage>30</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.revmed.2013.02.030</pub-id>
                    <pub-id pub-id-type="pmid">23523078</pub-id>
                    <issn>0248-8663</issn>
                </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>González-Gay</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>García-Porrúa</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Llorca</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hajeer</surname>
                     <given-names>AH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Brañas</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dababneh</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients</article-title>. 
                    <source>Medicine (Baltimore)</source>. 
                    <year>2000</year>
                    <month>Sep</month>;
                    <volume>79</volume>(
                    <issue>5</issue>):
                    <fpage>283</fpage>–
                    <lpage>92</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/00005792-200009000-00001</pub-id>
                    <pub-id pub-id-type="pmid">11039076</pub-id>
                    <issn>0025-7974</issn>
                </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>González-Gay</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blanco</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rodríguez-Valverde</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Martínez-Taboada</surname>
                     <given-names>VM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Delgado-Rodriguez</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Figueroa</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>1998</year>
                    <month>Aug</month>;
                    <volume>41</volume>(
                    <issue>8</issue>):
                    <fpage>1497</fpage>–
                    <lpage>504</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/1529-0131(199808)41:8&lt;1497::AID-ART22&gt;3.0.CO;2-Z</pub-id>
                    <pub-id pub-id-type="pmid">9704651</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Salvarani</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Della Bella</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cimino</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Macchioni</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Formisano</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bajocchi</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2009</year>
                    <month>Mar</month>;
                    <volume>48</volume>(
                    <issue>3</issue>):
                    <fpage>250</fpage>–
                    <lpage>3</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/ken465</pub-id>
                    <pub-id pub-id-type="pmid">19109317</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ninan</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lester</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hill</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant cell arteritis</article-title>. 
                    <source>Best Pract Res Clin Rheumatol</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>30</volume>(
                    <issue>1</issue>):
                    <fpage>169</fpage>–
                    <lpage>88</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.berh.2016.05.001</pub-id>
                    <pub-id pub-id-type="pmid">27421223</pub-id>
                    <issn>1521-6942</issn>
                </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Salvarani</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gabriel</surname>
                     <given-names>SE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>O’Fallon</surname>
                     <given-names>WM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hunder</surname>
                     <given-names>GG</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>1995</year>
                    <month>Mar</month>;
                    <volume>38</volume>(
                    <issue>3</issue>):
                    <fpage>369</fpage>–
                    <lpage>73</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.1780380311</pub-id>
                    <pub-id pub-id-type="pmid">7880191</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gran</surname>
                     <given-names>JT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Myklebust</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wilsgaard</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jacobsen</surname>
                     <given-names>BK</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2001</year>
                    <month>Nov</month>;
                    <volume>40</volume>(
                    <issue>11</issue>):
                    <fpage>1238</fpage>–
                    <lpage>42</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/40.11.1238</pub-id>
                    <pub-id pub-id-type="pmid">11709607</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gonzalez-Gay</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barros</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopez-Diaz</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Garcia-Porrua</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sanchez-Andrade</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Llorca</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients</article-title>. 
                    <source>Medicine (Baltimore)</source>. 
                    <year>2005</year>
                    <month>Sep</month>;
                    <volume>84</volume>(
                    <issue>5</issue>):
                    <fpage>269</fpage>–
                    <lpage>76</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/01.md.0000180042.42156.d1</pub-id>
                    <pub-id pub-id-type="pmid">16148727</pub-id>
                    <issn>0025-7974</issn>
                </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hunder</surname>
                     <given-names>GG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bloch</surname>
                     <given-names>DA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Michel</surname>
                     <given-names>BA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stevens</surname>
                     <given-names>MB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arend</surname>
                     <given-names>WP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Calabrese</surname>
                     <given-names>LH</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>1990</year>
                    <month>Aug</month>;
                    <volume>33</volume>(
                    <issue>8</issue>):
                    <fpage>1122</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.1780330810</pub-id>
                    <pub-id pub-id-type="pmid">2202311</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nesher</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The diagnosis and classification of giant cell arteritis</article-title>. 
                    <source>J Autoimmun</source>. 
                    <year>2014</year>
                    <month>Feb-Mar</month>;
                    <volume>48-49</volume>:
                    <fpage>73</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jaut.2014.01.017</pub-id>
                    <pub-id pub-id-type="pmid">24461386</pub-id>
                    <issn>0896-8411</issn>
                </mixed-citation>
         </ref>
         <ref id="b21">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Luqmani</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Singh</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gillett</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schmidt</surname>
                     <given-names>WA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bradburn</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study</article-title>. 
                    <source>Health Technol Assess</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>20</volume>(
                    <issue>90</issue>):
                    <fpage>1</fpage>–
                    <lpage>238</lpage>. 
                    <pub-id pub-id-type="doi">10.3310/hta20900</pub-id>
                    <pub-id pub-id-type="pmid">27925577</pub-id>
                    <issn>1366-5278</issn>
                </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Schmidt</surname>
                     <given-names>WA</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Role of ultrasound in the understanding and management of vasculitis</article-title>. 
                    <source>Ther Adv Musculoskelet Dis</source>. 
                    <year>2014</year>
                    <month>Apr</month>;
                    <volume>6</volume>(
                    <issue>2</issue>):
                    <fpage>39</fpage>–
                    <lpage>47</lpage>. 
                    <pub-id pub-id-type="doi">10.1177/1759720X13512256</pub-id>
                    <pub-id pub-id-type="pmid">24688604</pub-id>
                    <issn>1759-720X</issn>
                </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>YH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Choi</surname>
                     <given-names>SJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ji</surname>
                     <given-names>JD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Song</surname>
                     <given-names>GG</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis</article-title>. 
                    <source>Z Rheumatol</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>75</volume>(
                    <issue>9</issue>):
                    <fpage>924</fpage>–
                    <lpage>31</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00393-015-1674-2</pub-id>
                    <pub-id pub-id-type="pmid">26704559</pub-id>
                    <issn>0340-1855</issn>
                </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24. </label>
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hocevar</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rotar</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jese</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Semrl</surname>
                     <given-names>SS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pizem</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hawlina</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal Study</article-title>. 
                    <source>Medicine (Baltimore)</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>95</volume>(
                    <issue>14</issue>):
                    <fpage>e3210</fpage>. 
                    <pub-id pub-id-type="doi">10.1097/MD.0000000000003210</pub-id>
                    <pub-id pub-id-type="pmid">27057850</pub-id>
                    <issn>0025-7974</issn>
                </mixed-citation>
         </ref>
         <ref id="b25">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Unizony</surname>
                     <given-names>SH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fisheleva</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rowell</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schett</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spiera</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Design of the tocilizumab in giant cell arteritis trial</article-title>. 
                    <source>Int J Rheumatol</source>. 
                    <year>2013</year>;
                    <volume>2013</volume>:
                    <fpage>912562</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2013/912562</pub-id>
                    <pub-id pub-id-type="pmid">23653652</pub-id>
                    <issn>1687-9260</issn>
                </mixed-citation>
         </ref>
         <ref id="b26">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mukhtyar</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Guillevin</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cid</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>de Groot</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gross</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>European Vasculitis Study Group</collab>
                    </person-group>. 
                    <article-title>EULAR recommendations for the management of large vessel vasculitis</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2009</year>
                    <month>Mar</month>;
                    <volume>68</volume>(
                    <issue>3</issue>):
                    <fpage>318</fpage>–
                    <lpage>23</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/ard.2008.088351</pub-id>
                    <pub-id pub-id-type="pmid">18413441</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b27">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hoffman</surname>
                     <given-names>GS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cid</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hellmann</surname>
                     <given-names>DB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Guillevin</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stone</surname>
                     <given-names>JH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schousboe</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>International Network for the Study of Systemic Vasculitides</collab>
                    </person-group>. 
                    <article-title>A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2002</year>
                    <month>May</month>;
                    <volume>46</volume>(
                    <issue>5</issue>):
                    <fpage>1309</fpage>–
                    <lpage>18</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.10262</pub-id>
                    <pub-id pub-id-type="pmid">12115238</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b28">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Leon</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rodriguez Rodriguez</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morado</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rosales Rosado</surname>
                     <given-names>Z</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vadillo</surname>
                     <given-names>C</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Freites</surname>
                     <given-names>D</given-names>
                  </name>,
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice</article-title>. 
                    <source>Clin Exp Rheumatol</source>. 
                    <year>2018</year>
                    <month>Mar-Apr</month>;
                    <volume>36 Suppl 111</volume>(
                    <issue>2</issue>):
                    <fpage>121</fpage>–
                    <lpage>8</lpage>.
                    <pub-id pub-id-type="pmid">29303708</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b29">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Koster</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yeruva</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crowson</surname>
                     <given-names>CS</given-names>
                  </name>, 
                        
                        <name name-style="western">
                     <surname>Muratore</surname>
                     <given-names>F</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Labarca</surname>
                     <given-names>C</given-names>
                  </name>, 
                    </person-group>.
                    <source>Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study</source>.
                    <year>2019</year>
                    <month>May</month>;
                    <volume>46</volume>(
                    <issue>5</issue>):
                    <fpage>501</fpage>–
                    <lpage>8</lpage>.
                    <pub-id pub-id-type="doi">10.3899/jrheum.180429</pub-id>
                    <pub-id pub-id-type="pmid">30647171</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b30">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jover</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hernández-García</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morado</surname>
                     <given-names>IC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vargas</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bañares</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fernández-Gutiérrez</surname>
                     <given-names>B</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial</article-title>. 
                    <source>Ann Intern Med</source>. 
                    <year>2001</year>
                    <month>Jan</month>;
                    <volume>134</volume>(
                    <issue>2</issue>):
                    <fpage>106</fpage>–
                    <lpage>14</lpage>. 
                    <pub-id pub-id-type="doi">10.7326/0003-4819-134-2-200101160-00010</pub-id>
                    <pub-id pub-id-type="pmid">11177313</pub-id>
                    <issn>0003-4819</issn>
                </mixed-citation>
         </ref>
         <ref id="b31">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Diamantopoulos</surname>
                     <given-names>AP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hetland</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Myklebust</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series</article-title>. 
                    <source>BioMed Res Int</source>. 
                    <year>2013</year>;
                    <volume>2013</volume>:
                    <fpage>120638</fpage>. 
                    <pub-id pub-id-type="doi">10.1155/2013/120638</pub-id>
                    <pub-id pub-id-type="pmid">24106691</pub-id>
                    <issn>2314-6133</issn>
                </mixed-citation>
         </ref>
         <ref id="b32">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Voelker</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>A First for Giant Cell Arteritis</article-title>. 
                    <source>JAMA</source>. 
                    <year>2017</year>
                    <month>Jul</month>;
                    <volume>318</volume>(
                    <issue>1</issue>):
                    <fpage>20</fpage>.
                    <pub-id pub-id-type="pmid">28672299</pub-id>
                    <issn>1538-3598</issn>
                </mixed-citation>
         </ref>
         <ref id="b33">
            <mixed-citation publication-type="webpage">
                    <person-group person-group-type="author">
                        <collab>FDA</collab>
                    </person-group>. 
                    <article-title>FDA approves first drug to specifically treat giant cell arteritis</article-title>
                    <year>2017</year>.
                    [<date-in-citation content-type="access-date" iso-8601-date="2017-07-25">cited 2017 Jul 25</date-in-citation>]. 
                    <comment>Available from:<uri>https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm559791.htm</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b34">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Conway</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>O’Neill</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>O’Flynn</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gallagher</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>McCarthy</surname>
                     <given-names>GM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Murphy</surname>
                     <given-names>CC</given-names>
                  </name>, 
                        <etal>et al.</etal>
                    </person-group>
                    <article-title>Ustekinumab for the treatment of refractory giant cell arteritis</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>75</volume>(
                    <issue>8</issue>):
                    <fpage>1578</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/annrheumdis-2016-209351</pub-id>
                    <pub-id pub-id-type="pmid">27143653</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b35">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Conway</surname>
                     <given-names>R</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>O'Neill</surname>
                     <given-names>L</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Gallagher</surname>
                     <given-names>P</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>O'Flynn</surname>
                     <given-names>E</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Murphy</surname>
                     <given-names>C</given-names>
                  </name>,
                        <etal>et al</etal>
                    </person-group>.
                    <source>Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis. Abstract number 876</source>
                    <conf-name>2016 ACR/ARHP Annual Meeting</conf-name>;
                    <conf-date>November 11-16, 2016</conf-date>;
                    <conf-loc>Washington, DC</conf-loc>.
                    <comment>Available from:<uri>https://acrabstracts.org/abstract/long-term-efficacy-of-ustekinumab-for-the-treatment-of-giant-cell-arteritis/</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b36">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Diamantopoulos</surname>
                     <given-names>AP</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Haugeberg</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lindland</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Myklebust</surname>
                     <given-names>G</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?</article-title>
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2016</year>
                    <month>Jan</month>;
                    <volume>55</volume>(
                    <issue>1</issue>):
                    <fpage>66</fpage>–
                    <lpage>70</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/kev289</pub-id>
                    <pub-id pub-id-type="pmid">26286743</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b37">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Carbonella</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Berardi</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Petricca</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Biscetti</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alivernini</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bosello</surname>
                     <given-names>SL</given-names>
                  </name>, 
                        <etal>et al.</etal>
                    </person-group>
                    <article-title>Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone</article-title>. 
                    <source>J Am Geriatr Soc</source>. 
                    <year>2016</year>
                    <month>Mar</month>;
                    <volume>64</volume>(
                    <issue>3</issue>):
                    <fpage>672</fpage>–
                    <lpage>374</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/jgs.14004</pub-id>
                    <pub-id pub-id-type="pmid">27000356</pub-id>
                    <issn>0002-8614</issn>
                </mixed-citation>
         </ref>
         <ref id="b38">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Seelinger</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sznajd</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Judge</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Robson</surname>
                     <given-names>JC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Craven</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Jayne</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al.</etal>
                    </person-group>
                    <article-title>Predictors of Delay in Diagnosis of Giant Cell Arteritis and Antineutrophil Cytoplasm Antibody Associated Vasculitides: Analysis of Data from the Diagnostic &amp; Classification Criteria in Vasculitis Study</article-title>. 
                    <source>Rheumatology</source>. 
                    <year>2015</year>;
                    <volume>54</volume>:(
                    <issue>suppp_l</issue>):
                    <fpage>i172</fpage>–
                    <lpage>3</lpage>.
                    <issn>0080-2727</issn>
                </mixed-citation>
         </ref>
         <ref id="b39">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ezeonyeji</surname>
                     <given-names>AN</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Borg</surname>
                     <given-names>FA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Delays in recognition and management of giant cell arteritis: results from a retrospective audit</article-title>. 
                    <source>Clin Rheumatol</source>. 
                    <year>2011</year>
                    <month>Feb</month>;
                    <volume>30</volume>(
                    <issue>2</issue>):
                    <fpage>259</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10067-010-1616-y</pub-id>
                    <pub-id pub-id-type="pmid">21086005</pub-id>
                    <issn>0770-3198</issn>
                </mixed-citation>
         </ref>
         <ref id="b40">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Chandran</surname>
                     <given-names>AK</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Udayakumar</surname>
                     <given-names>PD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crowson</surname>
                     <given-names>CS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Warrington</surname>
                     <given-names>KJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matteson</surname>
                     <given-names>EL</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950-2009</article-title>. 
                    <source>Scand J Rheumatol</source>. 
                    <year>2015</year>
                    <month>May</month>;
                    <volume>44</volume>(
                    <issue>3</issue>):
                    <fpage>215</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.3109/03009742.2014.982701</pub-id>
                    <pub-id pub-id-type="pmid">25606666</pub-id>
                    <issn>0300-9742</issn>
                </mixed-citation>
         </ref>
         <ref id="b41">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Baldini</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maugeri</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ramirez</surname>
                     <given-names>GA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Giacomassi</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Castiglioni</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Prieto-González</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>64</volume>(
                    <issue>3</issue>):
                    <fpage>854</fpage>–
                    <lpage>65</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.33411</pub-id>
                    <pub-id pub-id-type="pmid">21989653</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b42">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ciccia</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rizzo</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maugeri</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alessandro</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Croci</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Guggino</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2016</year>;
                    <volume>76</volume>(
                    <issue>1</issue>):
                    <fpage>235</fpage>–
                    <lpage>43</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/annrheumdis-2016–209217</pub-id>
                    <pub-id pub-id-type="pmid">27098405</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b43">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Labarca</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Koster</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crowson</surname>
                     <given-names>CS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Makol</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ytterberg</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matteson</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2016</year>
                    <month>Feb</month>;
                    <volume>55</volume>(
                    <issue>2</issue>):
                    <fpage>347</fpage>–
                    <lpage>56</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/kev348</pub-id>
                    <pub-id pub-id-type="pmid">26385368</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b44">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Muller</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Devilliers</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Besancenot</surname>
                     <given-names>JF</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Manckoundia</surname>
                     <given-names>P</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant cell arteritis (Horton’s disease) in very elderly patients aged 80 years and older: A study of 25 cases</article-title>. 
                    <source>Geriatr Gerontol Int</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>16</volume>(
                    <issue>6</issue>):
                    <fpage>679</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/ggi.12536</pub-id>
                    <pub-id pub-id-type="pmid">26081629</pub-id>
                    <issn>1444-1586</issn>
                </mixed-citation>
         </ref>
         <ref id="b45">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Muratore</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kermani</surname>
                     <given-names>TA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crowson</surname>
                     <given-names>CS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Green</surname>
                     <given-names>AB</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Salvarani</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matteson</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Large-vessel giant cell arteritis: a cohort study</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>54</volume>(
                    <issue>3</issue>):
                    <fpage>463</fpage>–
                    <lpage>70</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/keu329</pub-id>
                    <pub-id pub-id-type="pmid">25193809</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b46">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Alba</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mena-Madrazo</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reyes</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Flores-Suárez</surname>
                     <given-names>LF</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant cell arteritis in Mexican patients</article-title>. 
                    <source>J Clin Rheumatol</source>. 
                    <year>2012</year>
                    <month>Jan</month>;
                    <volume>18</volume>(
                    <issue>1</issue>):
                    <fpage>1</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/RHU.0b013e31823e2e35</pub-id>
                    <pub-id pub-id-type="pmid">22157266</pub-id>
                    <issn>1076-1608</issn>
                </mixed-citation>
         </ref>
         <ref id="b47">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Alba</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>García-Martínez</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Prieto-González</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tavera-Bahillo</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Corbera-Bellalta</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Planas-Rigol</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients</article-title>. 
                    <source>Medicine (Baltimore)</source>. 
                    <year>2014</year>
                    <month>Jul</month>;
                    <volume>93</volume>(
                    <issue>5</issue>):
                    <fpage>194</fpage>–
                    <lpage>201</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/MD.0000000000000033</pub-id>
                    <pub-id pub-id-type="pmid">25181312</pub-id>
                    <issn>0025-7974</issn>
                </mixed-citation>
         </ref>
         <ref id="b48">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Singh</surname>
                     <given-names>AG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kermani</surname>
                     <given-names>TA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crowson</surname>
                     <given-names>CS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matteson</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Warrington</surname>
                     <given-names>KJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort</article-title>. 
                    <source>J Rheumatol</source>. 
                    <year>2015</year>
                    <month>Feb</month>;
                    <volume>42</volume>(
                    <issue>2</issue>):
                    <fpage>309</fpage>–
                    <lpage>15</lpage>. 
                    <pub-id pub-id-type="doi">10.3899/jrheum.140188</pub-id>
                    <pub-id pub-id-type="pmid">25512481</pub-id>
                    <issn>0315-162X</issn>
                </mixed-citation>
         </ref>
         <ref id="b49">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gonzalez-Gay</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Miranda-Filloy</surname>
                     <given-names>JA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lopez-Diaz</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perez-Alvarez</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gonzalez-Juanatey</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sanchez-Andrade</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study</article-title>. 
                    <source>Medicine (Baltimore)</source>. 
                    <year>2007</year>
                    <month>Mar</month>;
                    <volume>86</volume>(
                    <issue>2</issue>):
                    <fpage>61</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/md.0b013e31803d1764</pub-id>
                    <pub-id pub-id-type="pmid">17435586</pub-id>
                    <issn>0025-7974</issn>
                </mixed-citation>
         </ref>
         <ref id="b50">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Gonzalez-Gay</surname>
                     <given-names>MA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Castañeda</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Llorca</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Giant Cell Arteritis: Visual Loss Is Our Major Concern</article-title>. 
                    <source>J Rheumatol</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>43</volume>(
                    <issue>8</issue>):
                    <fpage>1458</fpage>–
                    <lpage>61</lpage>. 
                    <pub-id pub-id-type="doi">10.3899/jrheum.160466</pub-id>
                    <pub-id pub-id-type="pmid">27481989</pub-id>
                    <issn>0315-162X</issn>
                </mixed-citation>
         </ref>
         <ref id="b51">
            <mixed-citation publication-type="conference">
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Žigon</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lakota</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kuret</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tomšič</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Čučnik</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sodin-Šemrl</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al.</etal>, 
                        <role>eds</role>
                    </person-group>.
                    <article-title>Acute Phase Proteins and Interleukin-6 are Important in Distinguishing between Giant Cell Arteritis Positive and Negative Patients</article-title>. In:
                    <conf-name>10th international congress on autoimmunity</conf-name>;
                    <conf-date>6 - 10 April 2016</conf-date>;
                    <conf-loc>Leipzig, Germany</conf-loc>.
                    <comment>Available from:<uri>https://www.rsc.org/events/detail/18499/10th-international-congress-on-autoimmunity</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b52">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Deng</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Younge</surname>
                     <given-names>BR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Olshen</surname>
                     <given-names>RA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goronzy</surname>
                     <given-names>JJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Th17 and Th1 T-cell responses in giant cell arteritis</article-title>. 
                    <source>Circulation</source>. 
                    <year>2010</year>
                    <month>Feb</month>;
                    <volume>121</volume>(
                    <issue>7</issue>):
                    <fpage>906</fpage>–
                    <lpage>15</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.872903</pub-id>
                    <pub-id pub-id-type="pmid">20142449</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
         </ref>
         <ref id="b53">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hernández-Rodríguez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>García-Martínez</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Casademont</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Filella</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Esteban</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>López-Soto</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2002</year>
                    <month>Feb</month>;
                    <volume>47</volume>(
                    <issue>1</issue>):
                    <fpage>29</fpage>–
                    <lpage>35</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art1.10161</pub-id>
                    <pub-id pub-id-type="pmid">11932875</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b54">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Roblot</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morel</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lelievre</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gascan</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wijdenes</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lecron</surname>
                     <given-names>JC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Serum cytokine and cytokine receptor levels in patients with giant cell arteritis during corticotherapy</article-title>. 
                    <source>J Rheumatol</source>. 
                    <year>1996</year>
                    <month>Feb</month>;
                    <volume>23</volume>(
                    <issue>2</issue>):
                    <fpage>408</fpage>–
                    <lpage>10</lpage>.
                    <pub-id pub-id-type="pmid">8882065</pub-id>
                    <issn>0315-162X</issn>
                </mixed-citation>
         </ref>
         <ref id="b55">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Emilie</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liozon</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Crevon</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lavignac</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Portier</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liozon</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Production of interleukin 6 by granulomas of giant cell arteritis</article-title>. 
                    <source>Hum Immunol</source>. 
                    <year>1994</year>
                    <month>Jan</month>;
                    <volume>39</volume>(
                    <issue>1</issue>):
                    <fpage>17</fpage>–
                    <lpage>24</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/0198-8859(94)90096-5</pub-id>
                    <pub-id pub-id-type="pmid">8181959</pub-id>
                    <issn>0198-8859</issn>
                </mixed-citation>
         </ref>
         <ref id="b56">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lecron</surname>
                     <given-names>JC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Roblot</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chevalier</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Morel</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alderman</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gombert</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>High circulating leukaemia inhibitory factor (LIF) in patients with giant cell arteritis: independent regulation of LIF and IL-6 under corticosteroid therapy</article-title>. 
                    <source>Clin Exp Immunol</source>. 
                    <year>1993</year>
                    <month>Apr</month>;
                    <volume>92</volume>(
                    <issue>1</issue>):
                    <fpage>23</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/j.1365-2249.1993.tb05942.x</pub-id>
                    <pub-id pub-id-type="pmid">8096803</pub-id>
                    <issn>0009-9104</issn>
                </mixed-citation>
         </ref>
         <ref id="b57">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Roche</surname>
                     <given-names>NE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fulbright</surname>
                     <given-names>JW</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wagner</surname>
                     <given-names>AD</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hunder</surname>
                     <given-names>GG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goronzy</surname>
                     <given-names>JJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>1993</year>
                    <month>Sep</month>;
                    <volume>36</volume>(
                    <issue>9</issue>):
                    <fpage>1286</fpage>–
                    <lpage>94</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.1780360913</pub-id>
                    <pub-id pub-id-type="pmid">8216422</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b58">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>van der Geest</surname>
                     <given-names>KS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Abdulahad</surname>
                     <given-names>WH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rutgers</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Horst</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bijzet</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Arends</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2015</year>
                    <month>Aug</month>;
                    <volume>54</volume>(
                    <issue>8</issue>):
                    <fpage>1397</fpage>–
                    <lpage>402</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/keu526</pub-id>
                    <pub-id pub-id-type="pmid">25724206</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b59">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Terrier</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Geri</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Chaara</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Allenbach</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rosenzwajg</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Costedoat-Chalumeau</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2012</year>
                    <month>Jun</month>;
                    <volume>64</volume>(
                    <issue>6</issue>):
                    <fpage>2001</fpage>–
                    <lpage>11</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.34327</pub-id>
                    <pub-id pub-id-type="pmid">22147555</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b60">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ciccia</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alessandro</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rizzo</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Principe</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Raiata</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cavazza</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2011</year>
                    <month>Jul</month>;
                    <volume>63</volume>(
                    <issue>7</issue>):
                    <fpage>2097</fpage>–
                    <lpage>104</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.30374</pub-id>
                    <pub-id pub-id-type="pmid">21452292</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b61">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hicok</surname>
                     <given-names>KC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hunder</surname>
                     <given-names>GG</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goronzy</surname>
                     <given-names>JJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis</article-title>. 
                    <source>Ann Intern Med</source>. 
                    <year>1994</year>
                    <month>Oct</month>;
                    <volume>121</volume>(
                    <issue>7</issue>):
                    <fpage>484</fpage>–
                    <lpage>91</lpage>. 
                    <pub-id pub-id-type="doi">10.7326/0003-4819-121-7-199410010-00003</pub-id>
                    <pub-id pub-id-type="pmid">8067646</pub-id>
                    <issn>0003-4819</issn>
                </mixed-citation>
         </ref>
         <ref id="b62">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Panayi</surname>
                     <given-names>GS</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis</article-title>. 
                    <source>Br J Rheumatol</source>. 
                    <year>1990</year>
                    <month>Dec</month>;
                    <volume>29</volume>(
                    <issue>6</issue>):
                    <fpage>456</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/29.6.456</pub-id>
                    <pub-id pub-id-type="pmid">2124160</pub-id>
                    <issn>0263-7103</issn>
                </mixed-citation>
         </ref>
         <ref id="b63">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Beyer</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Axmann</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sahinbegovic</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Distler</surname>
                     <given-names>JH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Manger</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Schett</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2011</year>
                    <month>Oct</month>;
                    <volume>70</volume>(
                    <issue>10</issue>):
                    <fpage>1874</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/ard.2010.149351</pub-id>
                    <pub-id pub-id-type="pmid">21515917</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b64">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Seitz</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reichenbach</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bonel</surname>
                     <given-names>HM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adler</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wermelinger</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Villiger</surname>
                     <given-names>PM</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series</article-title>. 
                    <source>Swiss Med Wkly</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>141</volume>:
                    <fpage>w13156</fpage>.
                    <pub-id pub-id-type="doi">10.4414/smw.2011.13156</pub-id>
                    <pub-id pub-id-type="pmid">21515917</pub-id>
                    <issn>1424-3997</issn>
                </mixed-citation>
         </ref>
         <ref id="b65">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ferfar</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mirault</surname>
                     <given-names>T</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Desbois</surname>
                     <given-names>AC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Comarmond</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Messas</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Savey</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Biotherapies in large vessel vasculitis</article-title>. 
                    <source>Autoimmun Rev</source>. 
                    <year>2016</year>
                    <month>Jun</month>;
                    <volume>15</volume>(
                    <issue>6</issue>):
                    <fpage>544</fpage>–
                    <lpage>51</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.autrev.2016.02.012</pub-id>
                    <pub-id pub-id-type="pmid">26883459</pub-id>
                    <issn>1568-9972</issn>
                </mixed-citation>
         </ref>
         <ref id="b66">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Villiger</surname>
                     <given-names>PM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Adler</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kuchen</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wermelinger</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dan</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fiege</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial</article-title>. 
                    <source>Lancet</source>. 
                    <year>2016</year>
                    <month>May</month>;
                    <volume>387</volume>(
                    <issue>10031</issue>):
                    <fpage>1921</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00560-2</pub-id>
                    <pub-id pub-id-type="pmid">26952547</pub-id>
                    <issn>0140-6736</issn>
                </mixed-citation>
         </ref>
         <ref id="b67">
            <mixed-citation publication-type="conference">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Adler</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Reichenbach</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kuchen</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Wermelinger</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dan</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Seitz</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT. Abstract Number 867</article-title>. In:
                    <conf-name>2016 ACR/ARHP Annual Meeting</conf-name>;
                    <conf-date>November 11-16, 2016</conf-date>;
                    <conf-loc>Washington, DC</conf-loc>.
                    <comment>Available from:<uri>https://acrabstracts.org/abstract/long-term-efficacy-of-ustekinumab-for-the-treatment-of-giant-cell-arteritis/</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b68">
            <mixed-citation publication-type="conference">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Stone</surname>
                     <given-names>JH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tuckwell</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dimonaco</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Klearman</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Aringer</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blockmans</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial</article-title>.
                    <conf-name>2016 ACR/ARHP Annual Meeting</conf-name>;
                    <conf-date>November 11-16, 2016</conf-date>;
                    <conf-loc>Washington, DC</conf-loc>.
                    <comment>Available from:<uri>https://acrabstracts.org/abstract/long-term-efficacy-of-ustekinumab-for-the-treatment-of-giant-cell-arteritis/</uri>
               </comment>.
                </mixed-citation>
         </ref>
         <ref id="b69">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Régent</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Redeker</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Deroux</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kieffer</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ly</surname>
                     <given-names>KH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dougados</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>French Vasculitis Group, the Groupe Francais pour l’Etude de l’Artérite à Cellules Géantes, and the Club Rhumatismes et Inflammation</collab>
                    </person-group>. 
                    <article-title>Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients</article-title>. 
                    <source>J Rheumatol</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>43</volume>(
                    <issue>8</issue>):
                    <fpage>1547</fpage>–
                    <lpage>52</lpage>. 
                    <pub-id pub-id-type="doi">10.3899/jrheum.151252</pub-id>
                    <pub-id pub-id-type="pmid">27182063</pub-id>
                    <issn>0315-162X</issn>
                </mixed-citation>
         </ref>
         <ref id="b70">
            <mixed-citation publication-type="book-chapter">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dejaco</surname>
                     <given-names>C</given-names>
                  </name>
                    </person-group>. 
                    <chapter-title>Role of steroid-sparing agents</chapter-title>. In: 
                    <person-group person-group-type="editor">
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dejaco</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <role>editors</role>
                    </person-group>. 
                    <source>Polymyalgia Rheumatica and Giant Cell Arteritis</source>. 
                    <publisher-loc>Oxford</publisher-loc>: 
                    <publisher-name>Oxford University Press</publisher-name>; 
                    <year>2016</year>. pp. 
                    <fpage>89</fpage>–
                    <lpage>95</lpage>.
                </mixed-citation>
         </ref>
         <ref id="b71">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ly</surname>
                     <given-names>KH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stirnemann</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Liozon</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Michel</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fain</surname>
                     <given-names>O</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fauchais</surname>
                     <given-names>AL</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Interleukin-1 blockade in refractory giant cell arteritis</article-title>. 
                    <source>Joint Bone Spine</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>81</volume>(
                    <issue>1</issue>):
                    <fpage>76</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jbspin.2013.06.004</pub-id>
                    <pub-id pub-id-type="pmid">23890680</pub-id>
                    <issn>1297-319X</issn>
                </mixed-citation>
         </ref>
         <ref id="b72">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>
                    </person-group>. 
                    <article-title>A randomised, double-blinded, placebo controlled study to assess the efficacy and safety of gevokizumab in the treatment of giant cell arteritis. Second International Symposium and Imaging Workshop Giant Cell Arteritis, Polymyalgia Rheumatica and Large Vessel Vasculitis</article-title>. 
                    <source>Rheumatology</source>. 
                    <year>2014</year>;
                    <volume>53</volume>
                    <supplement>suppl.2</supplement>:
                    <fpage>i7</fpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/keu197</pub-id>
                    <issn>0080-2727</issn>
                </mixed-citation>
         </ref>
         <ref id="b73">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Espígol-Frigolé</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Corbera-Bellalta</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Planas-Rigol</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lozano</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Segarra</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>García-Martínez</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2013</year>
                    <month>Sep</month>;
                    <volume>72</volume>(
                    <issue>9</issue>):
                    <fpage>1481</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-201836</pub-id>
                    <pub-id pub-id-type="pmid">22993227</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b74">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Ciccia</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rizzo</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Guggino</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cavazza</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Alessandro</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Maugeri</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>54</volume>(
                    <issue>9</issue>):
                    <fpage>1596</fpage>–
                    <lpage>604</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/kev102</pub-id>
                    <pub-id pub-id-type="pmid">25862016</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b75">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>Q</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Yang</surname>
                     <given-names>W</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Gupta</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Biswas</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Smith</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Bhagat</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor</article-title>. 
                    <source>Immunity</source>. 
                    <year>2008</year>
                    <month>Dec</month>;
                    <volume>29</volume>(
                    <issue>6</issue>):
                    <fpage>899</fpage>–
                    <lpage>911</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.immuni.2008.10.011</pub-id>
                    <pub-id pub-id-type="pmid">19062315</pub-id>
                    <issn>1074-7613</issn>
                </mixed-citation>
         </ref>
         <ref id="b76">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Márquez</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hernández-Rodríguez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cid</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Solans</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Castañeda</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fernández-Contreras</surname>
                     <given-names>ME</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Spanish GCA Consortium</collab>
                    </person-group>. 
                    <article-title>Influence of the IL17A locus in giant cell arteritis susceptibility</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2014</year>
                    <month>Sep</month>;
                    <volume>73</volume>(
                    <issue>9</issue>):
                    <fpage>1742</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/annrheumdis-2014-205261</pub-id>
                    <pub-id pub-id-type="pmid">24919468</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b77">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Miossec</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kolls</surname>
                     <given-names>JK</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Targeting IL-17 and TH17 cells in chronic inflammation</article-title>. 
                    <source>Nat Rev Drug Discov</source>. 
                    <year>2012</year>
                    <month>Oct</month>;
                    <volume>11</volume>(
                    <issue>10</issue>):
                    <fpage>763</fpage>–
                    <lpage>76</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nrd3794</pub-id>
                    <pub-id pub-id-type="pmid">23023676</pub-id>
                    <issn>1474-1776</issn>
                </mixed-citation>
         </ref>
         <ref id="b78">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Blain</surname>
                     <given-names>H</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Abdelmouttaleb</surname>
                     <given-names>I</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Belmin</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blain</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Floquet</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Guéant</surname>
                     <given-names>JL</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Arterial wall production of cytokines in giant cell arteritis: results of a pilot study using human temporal artery cultures</article-title>. 
                    <source>J Gerontol A Biol Sci Med Sci</source>. 
                    <year>2002</year>
                    <month>Apr</month>;
                    <volume>57</volume>(
                    <issue>4</issue>):
                    <fpage>M241</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/gerona/57.4.M241</pub-id>
                    <pub-id pub-id-type="pmid">11909890</pub-id>
                    <issn>1079-5006</issn>
                </mixed-citation>
         </ref>
         <ref id="b79">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hernández-Rodríguez</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Segarra</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Vilardell</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Sánchez</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>García-Martínez</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Esteban</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2004</year>
                    <month>Mar</month>;
                    <volume>43</volume>(
                    <issue>3</issue>):
                    <fpage>294</fpage>–
                    <lpage>301</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/keh058</pub-id>
                    <pub-id pub-id-type="pmid">14679293</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b80">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Hoffman</surname>
                     <given-names>GS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cid</surname>
                     <given-names>MC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rendt-Zagar</surname>
                     <given-names>KE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Merkel</surname>
                     <given-names>PA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Stone</surname>
                     <given-names>JH</given-names>
                  </name>, 
                        <etal>et al</etal>; 
                        <collab>Infliximab-GCA Study Group</collab>
                    </person-group>. 
                    <article-title>Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial</article-title>. 
                    <source>Ann Intern Med</source>. 
                    <year>2007</year>
                    <month>May</month>;
                    <volume>146</volume>(
                    <issue>9</issue>):
                    <fpage>621</fpage>–
                    <lpage>30</lpage>. 
                    <pub-id pub-id-type="doi">10.7326/0003-4819-146-9-200705010-00004</pub-id>
                    <pub-id pub-id-type="pmid">17470830</pub-id>
                    <issn>0003-4819</issn>
                </mixed-citation>
         </ref>
         <ref id="b81">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Martínez-Taboada</surname>
                     <given-names>VM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rodríguez-Valverde</surname>
                     <given-names>V</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Carreño</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>López-Longo</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Figueroa</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Belzunegui</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2008</year>
                    <month>May</month>;
                    <volume>67</volume>(
                    <issue>5</issue>):
                    <fpage>625</fpage>–
                    <lpage>30</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/ard.2007.082115</pub-id>
                    <pub-id pub-id-type="pmid">18086726</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b82">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Seror</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Baron</surname>
                     <given-names>G</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hachulla</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Debandt</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Larroche</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Puéchal</surname>
                     <given-names>X</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>
                    <article-title>Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2014</year>
                    <month>Dec</month>;
                    <volume>73</volume>(
                    <issue>12</issue>):
                    <fpage>2074</fpage>–
                    <lpage>81</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-203586</pub-id>
                    <pub-id pub-id-type="pmid">23897775</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b83">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Langford</surname>
                     <given-names>CA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Cuthbertson</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ytterberg</surname>
                     <given-names>SR</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Khalidi</surname>
                     <given-names>NA</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Monach</surname>
                     <given-names>PA</given-names>
                  </name>,
                        <name name-style="western">
                     <surname>Carette</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>. 
                    <article-title>A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis</article-title>.
                    <source>Arthritis Rheumatol</source>
                    <year>2017</year>
                    <month>Apr</month>;
                    <volume>69</volume>(
                    <issue>4</issue>):
                    <fpage>837</fpage>–
                    <lpage>45</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.40044</pub-id>
                    <pub-id pub-id-type="pmid">28133925</pub-id>
                </mixed-citation>
         </ref>
         <ref id="b84">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Koster</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Matteson</surname>
                     <given-names>EL</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Warrington</surname>
                     <given-names>KJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis</article-title>. 
                    <source>Curr Opin Rheumatol</source>. 
                    <year>2016</year>
                    <month>May</month>;
                    <volume>28</volume>(
                    <issue>3</issue>):
                    <fpage>211</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/BOR.0000000000000265</pub-id>
                    <pub-id pub-id-type="pmid">26885650</pub-id>
                    <issn>1040-8711</issn>
                </mixed-citation>
         </ref>
         <ref id="b85">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Bhatia</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ell</surname>
                     <given-names>PJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Edwards</surname>
                     <given-names>JC</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis</article-title>. 
                    <source>Ann Rheum Dis</source>. 
                    <year>2005</year>
                    <month>Jul</month>;
                    <volume>64</volume>(
                    <issue>7</issue>):
                    <fpage>1099</fpage>–
                    <lpage>100</lpage>. 
                    <pub-id pub-id-type="doi">10.1136/ard.2005.036533</pub-id>
                    <pub-id pub-id-type="pmid">15958774</pub-id>
                    <issn>0003-4967</issn>
                </mixed-citation>
         </ref>
         <ref id="b86">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Mayrbaeurl</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hinterreiter</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Burgstaller</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Windpessl</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Thaler</surname>
                     <given-names>J</given-names>
                  </name>
                    </person-group>. 
                    <article-title>The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab</article-title>. 
                    <source>Clin Rheumatol</source>. 
                    <year>2007</year>
                    <month>Sep</month>;
                    <volume>26</volume>(
                    <issue>9</issue>):
                    <fpage>1597</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s10067-007-0684-0</pub-id>
                    <pub-id pub-id-type="pmid">17619810</pub-id>
                    <issn>0770-3198</issn>
                </mixed-citation>
         </ref>
         <ref id="b87">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Lally</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pernis</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Narula</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Huang</surname>
                     <given-names>WT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Spiera</surname>
                     <given-names>R</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis</article-title>. 
                    <source>Rheumatology (Oxford)</source>. 
                    <year>2015</year>
                    <month>Mar</month>;
                    <volume>54</volume>(
                    <issue>3</issue>):
                    <fpage>554</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/keu364</pub-id>
                    <pub-id pub-id-type="pmid">25213129</pub-id>
                    <issn>1462-0324</issn>
                </mixed-citation>
         </ref>
         <ref id="b88">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Piggott</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Deng</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Warrington</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Younge</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kubo</surname>
                     <given-names>JT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Desai</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis</article-title>. 
                    <source>Circulation</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>123</volume>(
                    <issue>3</issue>):
                    <fpage>309</fpage>–
                    <lpage>18</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.936203</pub-id>
                    <pub-id pub-id-type="pmid">21220737</pub-id>
                    <issn>0009-7322</issn>
                </mixed-citation>
         </ref>
         <ref id="b89">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Weyand</surname>
                     <given-names>CM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Goronzy</surname>
                     <given-names>JJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Immune mechanisms in medium and large-vessel vasculitis</article-title>. 
                    <source>Nat Rev Rheumatol</source>. 
                    <year>2013</year>
                    <month>Dec</month>;
                    <volume>9</volume>(
                    <issue>12</issue>):
                    <fpage>731</fpage>–
                    <lpage>40</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nrrheum.2013.161</pub-id>
                    <pub-id pub-id-type="pmid">24189842</pub-id>
                    <issn>1759-4790</issn>
                </mixed-citation>
         </ref>
         <ref id="b90">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Fernández-Fernández</surname>
                     <given-names>FJ</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Treg cells in giant cell arteritis: might they be another target for adjuvant treatment? Comment on the article by Samson et al</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>65</volume>(
                    <issue>1</issue>):
                    <fpage>289</fpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.37700</pub-id>
                    <pub-id pub-id-type="pmid">23001860</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b91">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Zold</surname>
                     <given-names>E</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Szodoray</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nakken</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Barath</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Kappelmayer</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Csathy</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease</article-title>. 
                    <source>Autoimmun Rev</source>. 
                    <year>2011</year>
                    <month>Jan</month>;
                    <volume>10</volume>(
                    <issue>3</issue>):
                    <fpage>155</fpage>–
                    <lpage>62</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.autrev.2010.09.018</pub-id>
                    <pub-id pub-id-type="pmid">20868777</pub-id>
                    <issn>1568-9972</issn>
                </mixed-citation>
         </ref>
         <ref id="b92">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Jeffery</surname>
                     <given-names>LE</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Burke</surname>
                     <given-names>F</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mura</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Zheng</surname>
                     <given-names>Y</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Qureshi</surname>
                     <given-names>OS</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hewison</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3</article-title>. 
                    <source>J Immunol</source>. 
                    <year>2009</year>
                    <month>Nov</month>;
                    <volume>183</volume>(
                    <issue>9</issue>):
                    <fpage>5458</fpage>–
                    <lpage>67</lpage>. 
                    <pub-id pub-id-type="doi">10.4049/jimmunol.0803217</pub-id>
                    <pub-id pub-id-type="pmid">19843932</pub-id>
                    <issn>0022-1767</issn>
                </mixed-citation>
         </ref>
         <ref id="b93">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Samson</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Audia</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fraszczak</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trad</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ornetti</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Lakomy</surname>
                     <given-names>D</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis</article-title>. 
                    <source>Arthritis Rheum</source>. 
                    <year>2012</year>
                    <month>Nov</month>;
                    <volume>64</volume>(
                    <issue>11</issue>):
                    <fpage>3788</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/art.34647</pub-id>
                    <pub-id pub-id-type="pmid">22833233</pub-id>
                    <issn>0004-3591</issn>
                </mixed-citation>
         </ref>
         <ref id="b94">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Berod</surname>
                     <given-names>L</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Friedrich</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Nandan</surname>
                     <given-names>A</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Freitag</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hagemann</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Harmrolfs</surname>
                     <given-names>K</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells</article-title>. 
                    <source>Nat Med</source>. 
                    <year>2014</year>
                    <month>Nov</month>;
                    <volume>20</volume>(
                    <issue>11</issue>):
                    <fpage>1327</fpage>–
                    <lpage>33</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nm.3704</pub-id>
                    <pub-id pub-id-type="pmid">25282359</pub-id>
                    <issn>1078-8956</issn>
                </mixed-citation>
         </ref>
         <ref id="b95">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Martinez-Taboada</surname>
                     <given-names>VM</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Blanco</surname>
                     <given-names>R</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Fito</surname>
                     <given-names>C</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Pacheco</surname>
                     <given-names>MJ</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Delgado-Rodriguez</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Rodriguez-Valverde</surname>
                     <given-names>V</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review</article-title>. 
                    <source>Semin Arthritis Rheum</source>. 
                    <year>2001</year>
                    <month>Feb</month>;
                    <volume>30</volume>(
                    <issue>4</issue>):
                    <fpage>257</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.1053/sarh.2001.9734</pub-id>
                    <pub-id pub-id-type="pmid">11182026</pub-id>
                    <issn>0049-0172</issn>
                </mixed-citation>
         </ref>
         <ref id="b96">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Elling</surname>
                     <given-names>P</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Olsson</surname>
                     <given-names>AT</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Elling</surname>
                     <given-names>H</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Reduced CD8+ T-cell concentration in peripheral blood of patients with carotid artery stenosis: relation to arteritis temporalis</article-title>. 
                    <source>Br J Rheumatol</source>. 
                    <year>1996</year>
                    <month>Jul</month>;
                    <volume>35</volume>(
                    <issue>7</issue>):
                    <fpage>649</fpage>–
                    <lpage>51</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/rheumatology/35.7.649</pub-id>
                    <pub-id pub-id-type="pmid">8670598</pub-id>
                    <issn>0263-7103</issn>
                </mixed-citation>
         </ref>
         <ref id="b97">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Samson</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ly</surname>
                     <given-names>KH</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Tournier</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Janikashvili</surname>
                     <given-names>N</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Trad</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Ciudad</surname>
                     <given-names>M</given-names>
                  </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Involvement and prognosis value of CD8(+) T cells in giant cell arteritis</article-title>. 
                    <source>J Autoimmun</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>72</volume>:
                    <fpage>73</fpage>–
                    <lpage>83</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.jaut.2016.05.008</pub-id>
                    <pub-id pub-id-type="pmid">27236507</pub-id>
                    <issn>0896-8411</issn>                    
                </mixed-citation>
         </ref>
         <ref id="b98">
            <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name name-style="western">
                     <surname>Nadkarni</surname>
                     <given-names>S</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dalli</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Hollywood</surname>
                     <given-names>J</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Mason</surname>
                     <given-names>JC</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Dasgupta</surname>
                     <given-names>B</given-names>
                  </name>, 
                        <name name-style="western">
                     <surname>Perretti</surname>
                     <given-names>M</given-names>
                  </name>
                    </person-group>. 
                    <article-title>Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression</article-title>. 
                    <source>Circ Res</source>. 
                    <year>2014</year>
                    <month>Jan</month>;
                    <volume>114</volume>(
                    <issue>2</issue>):
                    <fpage>242</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.301374</pub-id>
                    <pub-id pub-id-type="pmid">24158630</pub-id>
                    <issn>0009-7330</issn>
                </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
